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Abstract
Purpose: This paper reviews and reassesses the internationally accepted niches or ‘targets’ in bone marrow that are sensitive
to the induction of leukaemia and primary bone cancer by radiation.
Conclusions: The hypoxic conditions of the 10 mm thick endosteal/osteoblastic niche where preleukemic stem cells and
hematopoietic stem cells (HSC) reside provides a radioprotective microenvironment that is 2- to 3-fold less radiosensitive
than vascular niches. This supports partitioning the whole marrow target between the low haematological cancer risk of
irradiating HSC in the endosteum and the vascular niches within central marrow. There is a greater risk of induced bone
cancer when irradiating a 50 mm thick peripheral marrow adjacent to the remodelling/reforming portion of the trabecular
bone surface, rather than marrow next to the quiescent bone surface. This choice of partitioned bone cancer target is
substantiated by the greater radiosensitivity of: (i) Bone with high remodelling rates, (ii) the young, (iii) individuals with
hypermetabolic benign diseases of bone, and (iv) the epidemiology of alpha-emitting exposures. Evidence is given to show
that the absence of excess bone-cancer in atomic-bomb survivors may be partially related to the extremely low prevalence
among Japanese of Paget’s disease of bone. Radiation-induced ﬁbrosis and the wound healing response may be implicated in
not only radiogenic bone cancers but also leukaemia. A novel biological mechanism for adaptive response, and possibility of
dynamic targets, is advocated whereby stem cells migrate from vascular niches to stress-mitigated, hypoxic niches.
Keywords: cancer predisposition, bone, stem cells, radiation-induced tumours
Introduction
To assess the potential risk of radiation-induced
cancer, there is a need to calculate the absorbed dose
to radiosensitive tissues or ‘targets’ and to compare
this dose with the results of epidemiological studies.
Leukaemia and bone cancer contribute to the total
risk of cancer and hereditary disease estimated by the
committed effective dose as recommended in Pub-
lication 103 of the International Commission on
Radiological Protection (ICRP 103 2007). The long-
time ICRP target tissue for radiogenic bone cancer is
the 10 mm thick ‘‘endosteal layer’’ (ICRP 30 1979/
81) adjacent to trabecular and cortical bone surfaces
(Table I). This target was based on quiescent
osteoblasts/bone lining cells that are no longer
considered as possessing substantial carcinogenic
potential (ICRP 11 1968). In 2007, the ICRP
considered changing the thickness of the primary
bone cancer target adjacent to bone surface from 10–
50 mm (Bolch et al. 2007): This new thicker target
will be referred to as ‘‘peripheral marrow’’. Bone
cancer risk is assessed from the dose to peripheral
marrow found in trabecular bone cavities and
medullary (long bone) cavities in cortical bone,
now excluding cortical Haversian canals. The whole
red marrow including the endosteum continues to be
the ICRP’s target tissue for calculating dose and risk
of radiation-induced leukaemia.
The historical emphasis of the ICRP’s dosimetry
has been primarily for adults. This paper reviews
skeletal targets and proposes new ones suitable for all
ages of human development. Richardson (2009a)
assessed the risk of excess fatal cancers from internal
radionuclide exposures as the product of three
factors: the radiation hazard (excess mortality
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71), exogenous exposure (Bq) and internal ex-
posure dose coefﬁcient (Sv Bq
71). The National
Research Council publication Report V on the
Biological Effects of Ionising Radiations, i.e., BEIR
V (1990), estimated children were around 10 times
more vulnerable per unit dose (Sv
71) to fatal,
radiation-induced solid cancers than middle-aged
adults: leukaemia exhibited less variation with age.
Children take in smaller amounts of contaminated
air and food than adults. However, in smaller bodies,
radioactivity is more concentrated, turned over more
rapidly due to a higher metabolism and uptake in
organs elevated due to growth. The selection of
appropriate radiation targets for children that have
been internally exposed to bone-seeking radionu-
clides is important, as the infant:adult ratio of the
total fatal cancer risk per unit inhaled activity (Bq
71)
is around 10:1 (Richardson 2009a). Similarly, the
infant:adult risk per Bq ingested activity is *100:1.
The ICRP in 1989 extended radiation dosimetry
from adults to children and infants, and later added
the embryo/foetus (ICRP 56 1989, ICRP 88 2001).
The ICRP’s skeletal targets, developed for adults,
were recommended for assessing the radiation risk to
non-adults. However, unlike some soft tissue organs,
not only are the dimensions of the skeleton changed
by growth in childhood but there are also profound
age-related changes in skeletal physiology and
morphology.
Since 1979, when the endosteum and whole red
marrow were chosen as ICRP targets, there have
been signiﬁcant advances in the understanding of
radiation health effects and the biology of stem cells,
cancer stem cells, ﬁbrosis, inﬂammation and carci-
nogenesis. This paper was written to meet the
challenge set in 2007 by the ICRP Task Groups on
Internal Dosimetry (INDOS) and Dose Calculation
(DOCAL) to provide supporting biological and
epidemiological evidence for proposed partitioned
bone cancer and leukaemia targets. Nie and
Richardson (2009) modeled the dose to stem/
progenitor cells adjacent to the trabecular bone
remodelling compartment and found this site to be
a more likely candidate target for radiation-induced
bone cancers, especially in childhood, than the ICRP
target (i.e., the peripheral marrow adjacent to
quiescent bone surfaces). This new target is based
on the risk of bone cancer being higher when bone
turnover is elevated: this is the case in the young
rather than the old, in trabecular rather than cortical
bone, and in association with hyper-metabolic
pathology such as Paget’s disease (osteitis deformans
or osteodystrophia deformans).
The following dosimetry targets for ‘marrow
neoplasms’ (i.e., bone cancer and leukaemia) are
proposed as better representatives of radiation-
induced risk to the third trimester foetus and at all
post-natal ages (Figure 1):
. Leukaemia ‘partitioned hematopoietic targets’ –
instead of the ICRP’s whole red marrow,
trabecular hematopoietic tissue is partitioned into
two weighted parts: The endosteum/endosteal
niche (reduced weighting due to hypoxia) and the
remainder central cavity marrow.
. Bone cancer ‘partitioned peripheral marrow
targets’ – the ICRP’s whole peripheral marrow
is partitioned into two weighted parts: First,
peripheral marrow associated with quiescent
bone surfaces, and second, peripheral marrow
associated with forming bone surfaces.
. Both partitioned targets exclude marrow fat cells
that have low carcinogenic potential. The dose
associated with skeletal growth, remodelling and
forming surfaces can be weighted to represent the
greater cancer risk to children.
The contemporary knowledge on stem cells,
including their niches and oxygen levels, is reviewed
to determine the choice of marrow targets and their
Table I. Marrow niche characteristics of normal and cancer stem cells.
Endosteal/osteoblastic niche Vascular/endothelial niche References
Location in marrow 10 mm layer next to bone surfaces Hematopoietic tissue Lord (1990), Kiel et al. (2005)
Normal and cancer stem
cell replication
Mainly self-renewal of stem cells Mainly asymmetric
division (produce
differentiated progeny)
Arai and Suda (2007),
Eliasson and Jo ¨nsson (2010)
Normal stem cell activity Quiescent Rapid blood cell expansion Moore and Lemischka (2006),
Nagasawa (2006)
Cancer stem cell activity Quiescent Rapid primary/metastatic
tumour spread
Sipkins et al. (2005),
Ishikawa et al. (2007),
Medinger and Mross (2010)
O2 pressure (% atmospheric) 0.1–1% *7% Parmar et al. (2007),
Harrison (2002)
O2 enhancement ratio
(OER, low-LET)
1.1–1.4 2.5 Thoday and Read (1949),
Richardson (2008)
344 R. B. Richardsonradiosensitivity, especially taking infants and children
into account. It would be ideal if the calculated
radiation dose to targets always predicted risk, but
there are factors other than dose – such as cell
proliferation, genomic instability and the prevalence
of cell killing or pre-existing lesions – that affect the
risk of spontaneous and radiogenic neoplasms in
different populations (Streffer 2009). The inﬂuence
of pre-existing lesions on the occurrence of adult
radiogenic bone cancer was formulated a decade ago
(Go ¨ssner 1999). Since that time, the knowledge of
biological mechanisms of malignancy transformation
has advanced and may further explain the develop-
ment of radiation-induced neoplasms. Finally, exist-
ing and proposed marrow targets both have static
locations; but in future dynamic targets could be an
option as stem cells migrate in some circumstances.
Skeletal cancer targets lie primarily in
trabecular bone marrow
(1) Spontaneous and radiation-induced leukaemia
Leukaemia is the most common childhood cancer
(Table II), representing *31% of cancer cases in US
children under 15 years of age (Smith et al. 1999). In
US adults over 65 years old, leukaemia has *12
times higher incidence than in children, but makes
up only about one-fortieth of all cancers reported
(Ries et al. 2007). Acute myeloid leukaemia (AML),
chronic myeloid leukaemia (CML) and chronic
lymphocytic leukaemia (CLL) are primarily cancers
of old age, whereas acute lymphocytic leukaemia
(ALL) is particularly common in childhood. Most
leukaemias originate from precursor cells in bone
marrow (including B-cell lymphocytic leukaemias), a
Figure 1. Schematic diagrams (not to scale) depict trabecular marrow cavities that in reality are usually interconnecting. Sub-ﬁgure (A)
names the anatomical parts of a marrow cavity and shows the partitioned hematopoietic targets for leukemia, consisting of the endosteum
and central hematopoietic marrow and (B) shows the partitioned peripheral marrow targets for bone cancer consisting of quiescent surface
peripheral marrow (QSPM) and forming surface peripheral marrow (FSPM): the latter target could include the bone remodelling
compartment (BRC).
Table II. Characteristics of different types of leukaemia, namely their relative incidence levels of spontaneous occurrence at different stages of
human development and the stem or progenitor cells from which the leukaemic types originate (Ries et al. 2007). Note that the Philadelphia
chromosome is not only found in children with ALL but also found in adults with ALL, and occasionally those with AML (Jamieson et al.
2004)
a.
Acute myeloid
leukaemia (AML)
Chronic myeloid
leukaemia (CML)
Acute lymphocytic
leukaemia (ALL)
Chronic lymphocytic
leukaemia (CLL)
Spontaneous incidence Most common acute
leukaemia in adults
Occurs in middle aged
and elderly adults
Majority of childhood
leukaemia
Rare under 45 years of age
Hematopoietic
stem cell (HSC)
and its leukaemic
progenitors.
HSC, myeloid progenitors
a HSC, granulocyte-
macrophage
progenitors.
Usually Philadelphia
chromosome
translocation present
a
HSC, lymphoid
progenitors.
Majority are of
B cell lineage
a
HSC, lymphoid progenitors.
Great majority are
of B cell lineage
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represents about 15–20% (mostly in children) of
cases of ALL in Western countries. An advisory
group of the National Radiological Protection Board
(NRPB 2003) tasked with estimating the incidence
of different types of cancers for the UK population
reported that myeloid leukaemias made up just over
a third of spontaneous leukaemias, whereas radia-
tion-induced myeloid leukaemias, especially AML,
were over-represented compared to their lymphoid
counterparts (Table III). Thorotrast-administered
patients irradiated with high-linear-energy-transfer
(high-LET)
232Th alpha-radiation exhibit even great-
er domination by AML, *4/5ths of the leukaemia
cases. An excess risk of leukaemia is also associated
with the higher doses prescribed in radiotherapy for
cancer (Boice et al. 1987, Curtis et al. 1994) and X-
ray treatment of ankylosing spondylitis (Weiss et al.
1995). Thorotrast, radiotherapy and atomic-bomb
survivor studies all reported no radiation-induced
CLL (Preston et al. 1994). However, CLL’s rarity
among Asian populations, prolonged latency (per-
haps 20 years compared with *5 years for other
leukeamias), and misdiagnosis may have erroneously
designated CLL as a non-radiogenic form of cancer
(Richardson et al. 2005).
The excess relative risk of leukaemia in children or
adults exposed to the radiation dose from atomic
bombs dominated by low-LET high-energy gamma
rays is more than other cancers (Preston et al. 1994).
The evidence for lymphoma and multiple myeloma
in atomic-bomb survivors is weak or non-existent.
Brenner et al. (2003) found signiﬁcant excesses of
leukaemia in children reported for different public
and occupational populations exposed to ionising
radiation doses as low as a few mSv. The Oxford
survey is the largest case-controlled study of child-
hood cancers associated with obstetric X-rays, mean
dose 10–20 mGy (Bithell and Stewart 1975). This
study found, in common with other smaller case-
control studies, a proportional increase in risk of
*40% for childhood cancer (about half being
leukaemia) associated with prenatal irradiation (Doll
and Wakeford 1997). However, cohort studies of
medical or atom bomb in-utero irradiation provides
limited evidence of increased risk of cancer (ICRP 90
2003).
(2) Spontaneous and radiation-induced bone cancers
Sarcomas of the bone and cartilage are relatively rare
comprising about 0.2% of all malignancies in the
total US population (but a higher proportion of
childhood cancers, *6%) – an incidence rate similar
to other developed countries (Gurney et al. 1999,
Ghadirian et al. 2001, Ries et al. 2007). Chrondro-
sarcomas, derived from a mesenchymal cartilage
progenitor, are the spontaneous bone cancers most
frequent in adults; however, they occur about ﬁve
times less commonly as a fraction of radiation-
induced bone cancers (Table V). Osteosarcomas, an
osteoblastic neoplasm, are the most common form of
spontaneous and radiation-induced bone cancer in a
population, and are particularly prevalent in children
(Tables IV and V). A risk factor for osteosarcoma is
the rapid bone growth in adolescence. The intrame-
dullary form of osteosarcoma is most common
(*75%), the periosteum form makes up 4–10% of
cases, while intracortical osteosarcoma is rare
(51%) (Murphey et al. 1997). The remainder of
osteosarcomas is more deﬁned by histopathology
than their location in bone.
There is a low percentage of the spontaneous primary
bone tumours occurring in the cortical midshaft of long
bones, being about 10% of osteosarcomas, 10% of
chondrosarcomas and 14% of malignant ﬁbrous
histiocytomas, but these occurence drop to 2–6% for
post-irradiation bone sarcomas, including those
226Ra-
induced (Pool et al. 1983, Huvos 1991, Unni 1996).
Spiers and Beddoe (1983) found the frequency of
occurrence of spontaneous and radiation-associated
osteogenic sarcomas in the long bones of humans to be
more associated with the trabecular bone surface area
rather than the cortical surfaces.
In addition, Priest et al. (1995) showed that it is
rare for osteosarcomas to be induced in animals
following intakes of
226Ra and
241Am, both alpha-
emitters that deposit in locations of low bone
turnover (cortical or trabecular quiescent bone
surfaces). However, intakes of
224Ra and
239Pu are
much more toxic as they preferentially deposit in,
and irradiate, sites of high bone turnover, in
particular trabecular forming surfaces. In summary,
trabecular bone is an important potential bone
cancer site, whereas cortical bone is a minor target
for radiation bone cancer.
Table III. Comparison of the percentage incidence rates for
spontaneous and radiation-induced leukaemia (assuming 0%
radiation-induced CLL). The spontaneous incidence rates are
those of England and Wales from NRPB (2003)
a as given in their
Table 1.1. The low-LET incidence rates are those of the UK
population, also from NRPB (2003)
a as evaluated in their Table
4.3 based on the BEIR V (1990) risk model. The high-LET
incidence rates are those of Danish Thorotrast patients (Visfeldt
and Andersson 1995)
b.
AML CML ALL CLL
Spontaneous
a 27% 9% 9% 55%
Low-LET radiation
a 53% 22% 25% 0%
Thorotrast (high-LET)
b 80% 15% 5% 0%
AML, Acute myeloid leukaemia; CML, Chronic myeloid leukae-
mia; ALL, Acute lymphocytic leukaemia; CLL, Chronic lympho-
cytic leukaemia.
346 R. B. RichardsonNiches and oxygen levels of stem cells and
progenitor cells at risk
There are two major types of multipotent stem cells
found in the skeleton. First, hematopoietic stem cells
(HSC) form progenitors of both the myeloid and
lymphoid lineages including blood cells, immune
cells and osteoclasts that excavate bone. Second,
mesenchymal stem cells (MSC) produce bone
(osteoblasts), cartilage (chrondroblasts), fat and
stromal cells. Many, but probably not all, solid and
hematopoietic neoplasms arise from cancer stem
cells that are dysfunctional versions of a normal stem
cell. These cancer stem cells can self-renew and
differentiate into some or all cell types of the tumour
(Kelly et al. 2007). The concept of the cancer-stem
cell was ﬁrst developed in leukaemia (AML), but has
also been characterised in some solid cancers,
including bone tumours that arise from aberrant
MSC, e.g., osteosarcoma and chondrosarcoma,
(Hope et al. 2004, Gibbs et al. 2005). AML (arising
from aberrant HSC), but also CML and ALL have
been shown to be maintained by cancer stem cells
(Reya et al. 2001). Childhood ALL has been found
to be initiated in fetuses by primitive cells of the HSC
lineage acquiring characteristic chromosome trans-
locations; these rare mutated cells largely remain
covert and quiescent, with only some of them being
promoted postnatally to full, overt leukaemia
(Greaves et al. 2003). There is still much to learn
about radiation’s role in the origin of leukemic stem
cells, which can involve HSC that became abnormal
as a result of accumulated mutations or alternatively,
arise via progenitors that regain the stem cell
property of self-renewal (Passegue ´ et al. 2003).
Normal and cancer stem cells remain quiescent in
hypoxic niches, but migrate to or create vascular
niches in order to proliferate (Table I). This section
provides evidence for partitioning the ICRP’s leu-
kaemia and bone cancer targets based primarily on
the age-dependent locations of normal and cancer
stem/progenitor cells in marrow, and to a lesser
extent on the oxygen-dependent radiosensitivity of
their niches.
(1) Leukaemia: Age, cellularity and skeletal targets
Bone marrow is the major site of hematopoiesis in
the third trimester fetus, infants, children and
throughout adulthood (ICRP 70 1995). HSC are
Table V. Comparison of the percentage bone tumour incidence rates that occur spontaneously or are radiation-induced, including malignant
ﬁbrous histiocytoma (MFH). Other types of spontaneous malignant bone tumours than are named here make up 14% of tumour types
examined in ‘all population’ but only 3% of those aged 0–20 y (Unni 1996)
a. The Paget’s disease study was by Schajowicz et al. (1983)
b, the
radium values were reported by Go ¨ssner (1999)
c, the external irradiation of adults was based on the combined studies of Huvos (1991) and
Unni (1996)
d. Tucker et al. (1987)
e assessed the bone cancers developed after the radiotherapy treatment of childhood cancer.
Osteosarcoma Chondrosarcoma Fibrosarcoma/MFH Ewing’s sarcoma Number of individuals
Spontaneous, all population
a 41% 25% 8% 12%, 5,676
Spontaneous, 0–20 years old
a 61% 4% 4% 28% –
Paget’s disease, adults
b 63% 8% 27% 0% 62
224Ra,
226–228Ra, mainly adults
c 59% 7% 30% 0% 92
External radiation, mainly adults
d 63% 4% 33% 0% 246
External radiation of children
e 69% 17% 5% 5% 64
Table IV. Characteristics of different types of spontaneous and radiation-induced bone tumours (Ewing’s sarcoma is not associated with
radiation
a) including their relative incidence levels of spontaneous occurrence at different stages of human development, the stem or
progenitor cells from which the bone tumour types originate and their location in the skeleton (Gurney et al. 1999).
Osteosarcoma Chondrosarcoma Fibrosarcoma Ewing’s sarcoma
a
Spontaneous childhood
incidence
Most common Rare Almost unknown 2
nd most common
Spontaneous aged
adult incidence
2
nd most common Most common Rare Rare
Mesenchymal stem cell
(MSC) and its progenitors.
MSC, osteoblastic
progenitors
MSC, cartilage
progenitors
MSC, stromal progenitors MSC neural crest origin
Usual skeletal location Metaphysis of long bones Pelvis, leg bone
and arm bone.
Metaphysis or
diaphysis of long bones
Extremities and
central axis
Usual bone type Intramedullary
and periosteal
(Rare: intracortical)
Intramedullary Intramedullary and periosteal Intramedullary
and periosteal
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trabecular marrow with high hematopoietic cellular-
ity and little fat. The fetal marrow consists solely of
hematopoietic tissue, which is replaced by adipocytes
as the individual ages, dropping to an average skeletal
cellularity of *46% at 70 years old (Richardson and
Dubeau 2003). The loss of hematopoiesis in the
marrow of long bone cavities is faster in general than
in the rest of the skeleton: long bone medullary
cavities lack cellularity and hematopoiesis from
around 20 years onwards (Cristy 1981).
Acute and chronic leukaemia (Table II) is
characterised by unregulated growth of blood cells
and their precursors, with acute leukaemia involving
relatively immature cells (blasts) compared to the
more mature cell types of chronic leukaemia. A
CML blast crisis occurs in granulocyte-macrophage
progenitor cells that acquire self-renewal capability
(Jamieson et al. 2004). CML cases usually are
present in a chronic phase before progressing after
about three years on average, to an acute form of
leukaemia. The initial development of AML appears
to involve HSC, while subsequent mutations in
progenitors are necessary for full transformation
(Hope et al. 2004).
It is generally accepted that HSC and their
progenitors are located in two distinct microenviron-
ments or ‘niches’: Firstly, the endosteum or so-
called, osteoblastic niche and secondly, the sinusoi-
dal perivascular areas or vascular/endothelial niche
(Schoﬁeld 1978, Arai and Suda 2007, Lo Celso et al.
2009). Kiel et al. (2005) found that 14% of HSC in
murine bone marrow are associated with the
endosteum, while most HSC are in contact with
sinusoidal endothelia. Experimental evidence gener-
ally shows that quiescent HSC (slow cell turnover,
with most in the G0/G1 mitotic cell cycle phase),
other primitive hematopoietic progenitor cell types,
and AML stem cells, have their highest concentra-
tions close to bone surfaces (Lord 1990, Nagasawa
2006, Colmone et al. 2008, Ishikawa et al. 2007).
The 10 mm thick endosteum accommodates small,
3–7 mm diameter, spore-like stem cells (Vacanti
2004) accompanied by 1 mm thin osteoblasts that
are bone lining cells. Quiescent HSC may reside in
an osteoblastic niche in close contact with N-
cadherin
þ pre-osteoblastic cells and endothelial cells
that are MSC progeny, whereas active HSC prefer
peri-vascular niches containing mesenchymal reticu-
lar cells (Arai and Suda 2007, Kiel et al. 2007).
Less primitive progenitors, pre-leukemic cells and
malignant metastasising cells migrate towards the
vascular sinusoids located in the central part of
marrow in bone cavities (Colmone et al. 2008).
Perivascular sites provide nutrients and vascular
access to mitotically active cancer stem cells, as well
as beneﬁting HSC/MSC and their differentiated
progenitors that replenish the blood system (Sipkins
et al. 2005, Kopp et al. 2005). The presence of
endosteal and vascular niches supports the proposed
partitioning of ICRP’s whole marrow target for
leukaemia, especially considering that these locations
have differing radiosensitivity as described in sub-
section (3) below.
(2) Bone cancer: Age, cellularity and skeletal targets
During the third month after conception, a primary
then secondary ossiﬁcation centre is formed in long
bones; both ossiﬁcation centres produce cartilage
cavities that ﬁll with marrow. The epiphyseal growth
plate produces longitudinal bone growth, while the
periosteum provides appositional growth. This ske-
letal growth is active in the infant, peaks in the
adolescent and ends in the young adult: Bone
remodelling activity mirrors that of growth but
continuing at a low level into old age. In childhood,
the spontaneous and radiation-induced bone cancer
incidences shows a similar trend to bone growth.
The proportions of trabecular bone and cortical bone
vary with age, being predominantly trabecular/
cancellous bone in the fetus and newborn when
skeletal remodelling and proliferative activity is at its
maximum (ICRP 70 1995). Cortical bone, which
dominates in adults, comprises 80% of the skeletal
mass and has a turnover six times slower than
trabecular bone. In infants (when cortical bone is
scarce), forming surfaces consist of up to 50% of
trabecular bone surfaces, while in adults this ﬁgure
drops to only 3% of cortical bone surfaces and 6% of
trabecular bone surfaces.
Human MSC that differentiate into connective
tissue cells with osteogenic and chrondrogenic
potential are resident in many sites including bone
growth plates, the outer cambian layer of the
periosteum, and within Haversian canals of cortical
bone (Muschler et al. 2003). MSC, originally
referred to as colony-forming unit-ﬁbroblasts, sup-
port hematopoiesis and osteogenesis, but unlike
HSC do not exhibit all stem-cell criteria as they
have a more limited capacity for self-renewal and
cannot regenerate a whole tissue. Like HSC, MSC
seem to occupy two distinct marrow niches (Bianco
et al. 2001). Active MSC occupy vascular niches in
association with endothelial cells and quiescent MSC
are found in close proximity to trabeculae bone
surfaces. The number of osteoblastic stem cells,
osteoblastic progenitors and osteoblasts in marrow
markedly decreases with age after skeletal maturation
(Nishida et al. 1999, Muschler et al. 2001).
Osteoblast and MSC concentrations, like bone
turnover, were observed to be inversely associated
to the adiposity of marrow (Moerman et al. 2004). In
children, spontaneous and radiation-induced bone
348 R. B. Richardsoncancers are primarily metaphyseal and diaphyseal
intramedullary lesions, although benign tumours
(e.g., chondroblastoma) are commonly associated
with growth plates (Table II). In adults, spontaneous
and radiation-induced bone cancers also usually
originate in trabecular bone with red marrow, e.g.
proximal/distal ends of long bones (Spiers and
Beddoe 1983). Trabecular cavity marrow generally
exhibits high cellularity and MSC levels, which result
in a higher proliferative capacity than cortical bone.
The skeletal location of MSC and radiogenic bone
cancers support the selection of a radiation target for
bone cancer that is associated with remodelling bone
found on trabecular bone surfaces.
(3) Oxygen effect and radioprotection of quiescent stem
cells
The preferred microenvironments of differentiated
and undifferentiated cells in bone marrow have
radically different oxygen tensions and oxygen
consumption levels. In a hypoxic environment, stem
cells have a low metabolism and a long lifespan.
However, stem cells and their shorter-lived progeni-
tors proliferate under higher oxygen pressures. The
presence of the hypoxic marker pimonidazole de-
monstrates that HSC in bone marrow are mostly
located in the endosteum at 1% O2 or less,
i.e.,51 kPa or 7.6 torr (Parmar et al. 2007). The
self-renewal of HSC or MSC, and their maintenance
in an undifferentiated state, is enhanced in hypoxic
conditions existing close to bone surfaces compared
with normoxic conditions found elsewhere in mar-
row (Grayson et al. 2006). Reactive oxygen species
(ROS) arise from exogenous radiation sources, but
mostly originate from endogenous mitochondria.
The transcription factor, hypoxia-inducible factor-
1, (HIF-1) adapts cells to survive the stress of low
oxygen conditions (Papandreou et al. 2006). In
hypoxic regions, glycolysis is stimulated, oxidative
phosphorylation becomes more efﬁcient, and mito-
chondrial proton leakage and cell death are repressed
(Gnaiger et al. 2000). Therefore, hypoxia and the
‘oxygen effect’ protect normal stem cells from ROS,
thereby reducing the consequential DNA damage
and apoptosis (Moore and Lemischka 2006, Arai
and Suda 2007). Similarly, quiescent leukemic stem
cells residing in the hypoxic endosteum are resistant
to radio- and chemo-therapy and treatment-induced
ROS (Ishikawa et al. 2007).
The oxygen enhancement ratio (OER) value is
deﬁned as the ratio of the hypoxic and normoxic
doses which lead to the same biological effect, such
as cell death (Thoday and Read 1949). Radio-
sensitivity varies most rapidly with oxygen tensions
below about 2% O2. The maximum OER value
increases with decreasing LET (particle keV lost per
mm of track). For example, the OER value utilised by
Richardson (2008) for low LET X-rays, was 2.6 in
air (21% O2). The maximum OER value is 1.3 for
high-LET 4.0 MeV alpha particles from
232Th decay,
compared to a maximum OER of 1.7 for
224Ra alpha
particles of 5.7 MeV. Therefore, any deleterious
radiation effects to MSC, HSC or cancer stem cells
residing in the radioprotective microenvironment of
the endosteum, compared with radiosensitive vascu-
lar niches, will be mitigated by a factor of, at most,
two for high LET alpha-radiation and three for low
LET beta-, gamma- and X-rays (Table I). The
radioresistance of the narrow endosteum will have a
minor inﬂuence on the overall higher radiosensitivity
of the 50 mm thick peripheral marrow that encom-
passes it.
The match/mismatch between dosimetry and
epidemiological leukaemia incidence
When selecting radiation targets one important aim is
for the target dose (Gy) to correspond with the cancer
incidence risk obtained from epidemiological studies.
This is particularly difﬁcult to achieve for low doses
and low dose rates. The choice of target is complicated
by factors other than radiation dose that affect the risk
of fatal cancer. This section reviews two biological
mechanisms that may inﬂuence risk: First, cell killing,
which has been known for decades to decrease high
dose response, and second, recent research on
radiation-associated migration of HSC that is hypothe-
sised to be a form of adaptive response.
(1) Leukaemia risk is reduced by high dose cell killing
Low-LET studies of medical irradiation for Japanese
atomic-bomb survivors show a curvilinear dose
response for leukaemia, with comparatively lower
risk at doses below *1 Gy, and cell sterilisation from
3 Gy upwards (Pierce et al. 1996, Little et al. 1999).
The leukemic risk and cell killing from this low-LET
acute irradiation is compared next with observations
from two studies where patients were administered
radium and thorium radionuclides and received
internal, high dose, high-LET exposures.
German patients, mostly adults, during the 1940s
and 50s were treated with multiple injections of
bone-seeking radium alpha-emitters for various
conditions (Nekolla et al. 2005, Wick and Nekolla
2005). Excess leukaemia was induced when low
doses of short-lived
224Ra were administered to
ankylosing spondylitis patients (Harrison and Muir-
head 2003). However, there were lower incidences of
leukaemia than expected observed in high dose
studies of long-lived
226Ra alpha-emitters, including
radium dial painters (Spiers et al. 1983). Thorotrast,
a thorium dioxide colloid containing
232Th and its
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radiographic contrast medium in the 1930s and
40s. The alpha-radiation exposure of the liver, spleen
and bone marrow was long term and probably
homogeneously distributed within these organs and
tissues. Harrison and Muirhead (2003) compared
the risk of radiation-induced leukaemia in patients
that received Thorotrast alpha-irradiation with atom-
ic-bomb survivors that were exposed to high-energy
gamma rays. When the ICRP value of 20 is employed
as the alpha-radiation weighting factor, the hemato-
poietic malignancies of the Thorotrast exposures
were 10 times lower than expected (van Kaick and
Wesch 2005). These high alpha-radiation doses
sterilised hematopoietic progenitors reducing malig-
nancies (Go ¨ssner 2003).
Cardis et al. (1995) conducted the largest inter-
national combined study of nuclear industry workers
assessing the health risks associated with low dose,
mainly low-LET external exposures. The review of
these occupational exposures by BEIR VII (2006)
concluded that although the risk estimates for
leukaemia varied considerably, they were consistent
with those on which current radiation protection
recommendations are based. Therefore, the current
ICRP whole-marrow target for radiation-induced
leukaemia provides a reasonable estimate of the
haematological cancer risk for low-LET external
exposures of adults. Whereas, dosimetric evaluations
for high-dose, short-range, high-LET, internal irra-
diations, based on the same target, appear to over-
emphasise the risk. This poor assessment of cancer
risk is primarily due to cell killing. But could an
adaptive response also be playing a role by
reducing the biological effects of the internal, chronic
irradiation?
(2) Stem cells migrate after a radiation-insult as an
adaptive response?
There is a higher excess relative risk of leukaemia
after whole body irradiation of atomic-bomb survi-
vors compared to the risk of leukaemia as a second
cancer in patients treated for cervical cancer and
uterine cancer with partial-body external beam
radiation (Boice et al. 1987, Curtis et al. 1994, Little
2001). Shuryak et al. (2006) contend that the lower
leukemogenic risk for partial-irradiation is due to
HSC migrating through the blood stream, from
niches in bone marrow and spleen that received low
doses, to repopulate high dose sites where stem cells
have been inactivated. Medical irradiations, often
concurrent with chemotherapy, generally involve
multiple acute external beam exposures or chronic
brachytherapy exposures. It is hypothesised that an
early adaptation to the ongoing stress of multiple
exposures may reduce the risk of a second cancer.
Real-time imaging has been recently employed to
show the localisation of HSC and progenitor cells in
medullary cavities of femurs from un-irradiated and
irradiated mice. Xie et al. (2009) found HSC
randomly distributed in the marrow within 50 mm
of the trabecular bone surface of irradiated mice.
Controversially, Lo Celso et al. (2009), like some
others before them, contend that HSC are normally
sparsely localised, if at all, within 30 mm of the
endosteum (Kiel et al. 2007). In both studies, other
mice were also imaged after receiving around 10 Gy
before bone marrow transplantation. HSC were then
injected into the irradiated recipients and they
localised closer to the endosteal surface than in the
unirradiated mice: of the HSC, 47% were now
within 15 mm of the endosteal surface according to
Lo Celso et al. (2009).
There appears to be good biological reasons to
support marrow stem cells being normally located in
the vascular niche, but migrating to the endosteal
niche in times of physiological stress. A vascularised
and well-oxygenated environment provides the es-
sential nutrients for production of progeny and DNA
repair by homologous recombination, the latter an
energetically demanding but virtually error-free
process. Under stress, stem cells that migrate to the
hypoxic endosteum will experience the advantages of
less free-radical damage due to reduced endogenous
and exogenous ROS, as well as increased self-
renewal and longevity (Eliasson and Jo ¨nsson 2010).
Ionising radiation, especially alpha-particles, pro-
duce comparatively more DNA double strand breaks
than mitochondrial proton leakage. A downside of
hypoxia is slow HSC turnover (*1 year in non-
human primates) and reduced DNA repair (Mah-
mud et al. 2001). This leads to a greater reliance on
double-strand breaks being repaired by error-prone
replication-independent processes (Rodrı ´guez-Jime ´-
nez et al. 2008). No matter what, the long-term
stress associated with ageing will result in stem cells,
even if quiescent, accumulating mutations and
exhibiting shorter telomeres, as well as accelerated
stem cell exhaustion and senescence (Nijnik et al.
2007; Richardson 2009b).
Several biological mechanisms – including DNA-
repair processes, apoptosis, and the immune re-
sponse – have been expounded in the literature to
explain the adaptive response of somatic cells to
stress, such as heat or radiation (Streffer 2009). In
many situations a protective adaptive response by
radiation is demonstrated by a low acute dose of 5–
200 mGy, given 4–24 h before a higher challenging
dose of 1 to several Gy. The mice in the experiments
of Lo Celso et al. (2009) and Xie et al. (2009) were
irradiated at higher levels than for adaptive response
experiments in general. After Xie et al. (2009)
exposed their mice to 10 Gy, and in response to
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into the radioprotective endosteum, which they then
occupied for410 months. It would be of interest to
learn if this migratory behaviour of stem cells from a
vascular niche to a hypoxic one occurs for shorter
times at the lower doses usually employed to
demonstrate adaptive response; and in addition, to
also determine if this adaptation is responsible for
reducing the late effects of multiple or chronic
radiation doses compared with acute exposure.
Biological mechanisms linking radiogenic
ﬁbrosis and marrow cancers
Although the targets proposed were selected to allow
a prediction of excess cancers attributable to the
radiation dose, there are other factors besides dose
that inﬂuences the risk. This section reviews the
evidence that ﬁbrosis and pre-existing lesions are
associated with aging and radiation-induced bone
cancer. Conversely, it is suggested that where
population groups display a rarity of these lesions,
as for all children and Asians adults, this will modify
the risk of this lesion-associated, late-effect neoplas-
tic development. Therefore, the bone cancer targets
of children and adults will differ as different factors
such as pre-existing lesions and growth inﬂuence
their risk. Lastly, this section reviews the recently
published research on biological mechanisms which
may suggest a link between radiation, inﬂammation,
ﬁbrosis and leukaemia.
(1) Pre-existing lesions, ﬁbrosis and radiation-induced
bone cancer in adults
Several researchers have observed that following a
radium intake a mainly acellular, ﬁbrotic layer forms
on bone surfaces. Lloyd and Henning (1983)
contended that this 8–50 mm thick microenviron-
ment found in the neighbourhood of a bone tumour
predisposed the site to radiation-induced bone
cancers. Go ¨ssner (1999) hypothesised that pre-
existing lesions (e.g., Paget’s disease, bone infarct,
ﬁbrous dysplasia), or radiation-induced bone lesions
(e.g., radiation osteitis), and associated ﬁbrosis might
be critical for the induction of bone sarcomas of
ﬁbroblastic and ﬁbrohistiocytic origin. The case is
made in the next subsection that this hypothesis is
more relevant to adults than children. Go ¨ssner’s
observation was made on the evidence that adults
receiving radium or external beam radiotherapy
showed the same spectrum of bone tumour types
as adults with pre-existing bone lesions (rows 4, 5, 6;
Table V). For example, in patients with Paget’s
disease Schajowicz et al. (1983) reported a high
fraction (27%) of ﬁbrosarcomas and malignant
ﬁbrous histiocytomas (row 4, Table V). In a
population comprising of mainly adults, ﬁbrosarco-
ma and malignant ﬁbrous histiocytoma are about
three times more prevalent as a radiation-induced
tumour than as a spontaneous tumour (rows 2, 5, 6;
Table V).
Similar to radiation-induced cataracts, alpha par-
ticle irradiation of the skeleton appears to have a
deterministic effect by inducing premature aging,
probably by increased inﬂammation and ﬁbrosis, the
depletion of stem cells in marrow, and increased
mutations of the remainder stem cells (Richardson
2009b). The average age of female US radium-dial
painters at ﬁrst exposure was just 20+5 years old
(Rowland et al. 1983). The appearance time of the
226,228Ra-induced bone sarcomas was long, on
average 27+14 years. The latent period was
shortened dependent on the average skeletal dose.
With the characteristics of a dose threshold, at lower
doses the aging effect in these young women was
small and inconsequential, as the cancer induction
period was likely greater than the human life span
(Evans et al. 1969).
Unlike leukaemia, bone sarcomas are rarely
induced below skeletal doses less than 10 Gy
(Brenner et al. 2003). This applies to adult radium-
dial painters (BEIR IV 1988), Mayak workers
exposed to plutonium (Shilnikova et al. 2003),
ankylosing spondylitis patients treated with
224Ra
(Wick and Nekolla 2005), and children receiving
radiotherapy (Tucker et al. 1987). The high dose
threshold for radiogenic bone cancer may be related
to the ﬁnding that at low or moderate doses most
tissues/organs studied express more ﬁbrosis cytokine
than bone marrow (Chang et al. 1995, Martin et al.
2000): the possible involvement of this biological
mechanism is explored further in subsection (4)
below. In light of the association of radiogenic bone
cancer and ﬁbrosis, Lloyd and Henning (1983),
supported by Go ¨ssner (2003), proposed increasing
the thickness of the ICRP radiation target from the
endosteum of 10 mm thickness to a 50 mm marrow
layer adjacent to the bone surface, where ﬁbrosis
associated with spontaneous or radiation-induced
bone lesions is commonly located.
(2) Higher bone cancer rates in children are not
associated with pre-existing lesions
Children and adults receiving high medicinal doses
of
224Ra had a statistically signiﬁcant increase in
bone cancer risk with decreasing age at exposure
(Nekolla et al. 2005). In patients treated for
tuberculosis and other diseases by an injectant
containing
224Ra, the incidence of bone sarcoma
was about 14 times higher in the 1- to 5-year-olds,
compared to adults420 years old (Spiess 1969).
Children receiving radiotherapy had an increased
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et al. 1987). The mean period from the treated ﬁrst
cancer to the secondary bone cancer was around 10
years, a shorter latency than for adults receiving
similar therapy.
Pre-existing lesions of bone are more common in
adults, whereas benign tumours are more common
in children. Around half of spontaneous bone
tumours in American children are non-malignant
(Unni 1996), although the transformation from
benign to malignant form is rare. Children receiving
radiotherapy developed malignant bone cancers of a
similar type to those arising in a population
spontaneously, but with a lower incidence of Ewing’s
sarcoma (rows 3, 7; Table V). Irradiated children
developed fewer bone sarcomas of ﬁbroblastic and
ﬁbrohistiocytic origins (Tucker et al. 1987); these
sarcomas are relatively common among the radia-
tion-induced bone cancers of adults (see previous
subsection). The ICRP justiﬁes the employment of a
peripheral marrow target on the basis that radiogenic
cancers are associated with ﬁbrosis or pre-existing
lesions. Although, Go ¨ssner’s (1999) observation is
important for adults, it has little relevance to
irradiated infants and children for whom pre-existing
lesions and ﬁbrosarcoma/malignant ﬁbrous histiocy-
toma are rare. Instead, rapid skeletal remodelling
and growth are probably the dominant factors linked
with both spontaneous and radiogenic bone cancers
of children and adolescents, thereby supporting the
partitioning (and perhaps age-dependent weighting)
of the peripheral marrow target into that associated
with quiescent and forming bone surfaces.
(3) Rarity of Paget’s disease and lack of bone cancer in
Japanese atomic-bomb survivors.
Paget’s disease of bone has a strong genetic
component (Albagha et al. 2010) and is very
common in some elderly Caucasian populations in
Europe and US; it is less common in Scandanavia
and extremely rare in Asia and Africa (Hashimoto
et al. 2006). Paget’s disease is characterised, similar
to radiation osteitis, by abnormal and rapid osseous
remodelling. It is rarely found in adults under 45
years old and becomes more common with ageing
(Cooper et al. 2006). The disease is a benign
condition with the potential for malignant transfor-
mation. Those with Paget’s disease have an approxi-
mately 10-fold higher risk than the general
population in developing bone sarcomas (Wick
et al. 1981, Ghadirian et al. 2001). In most
countries, Paget’s disease is estimated to occur in
0.1–5% of individuals. However, in Japan, sponta-
neous bone cancer rates, including those in child-
hood, are relatively low when compared to
international values (Parkin et al. 1993). In parti-
cular, there are low incidences of osteosarcoma in
Japanese and Chinese adults aged over 50 years,
which could be related to the lack of Paget’s disease
(Guo et al. 1999).
While a signiﬁcant increase in bone-cancer mor-
tality has been seen in adult radium dial painters in
Europe and the US, bone cancer is among the few
exceptions to the full spectrum of spontaneous
cancers reported in excess among adult atomic-
bomb survivors exposed to relatively low doses
(Brenner et al. 2003, Preston et al. 2007, Richardson
2009b). It is acknowledged that the characteristics of
these two radiation exposures were very different in
terms of homogeneity and duration of the exposures,
the mean dose, LET and relative biological effec-
tiveness (RBE). Nevertheless, Little (2001) found a
strong increasing trend of bone cancers with atomic-
bomb dose for those exposed as children (excess
relative risk, 16.5), even though there was no
signiﬁcant association for adult-exposed survivors
(excess relative risk, 70.3).
One reason for the relative lack of excess bone
cancers in atomic-bomb survivors could be due to
only 323 of the 86,661 exposed survivors having
whole body (life-threatening) doses over 4 Gy (Pierce
et al. 2008) and possibly none exceeding a 10 Gy
skeletal dose threshold. Even if radiation can induce
bone cancers at doses510 Gy, a second factor may
be the extremely low prevalence of Paget’s disease in
Japan, estimated at just 2.8 cases per million capita
(Hashimoto et al. 2006). Follow-up studies of
patients administered alpha-emitting Thorotrast
(Mori et al. 2005, van Kaick and Wesch 2005) have
exhibited excess bone cancers at signiﬁcantly higher
incidences (p50.05) in at least four of the six
countries studied. Further analysis may provide the
opportunity to statistically determine if irradiated
adults from countries where Paget’s disease of bone
is very common (i.e., Germany, Portugal and the
US) have a higher predilection to develop excess
bone sarcomas than citizens from countries where
Paget’s disease is uncommon or extremely rare (i.e.,
Denmark, Sweden and Japan). Therefore, it appears
the ICRP’s present bone cancer target, the peripheral
marrow adjacent to quiescent surfaces, has limited
relevance to Asian and Nordic adults, and children
globally, for whom pre-existing bone lesions are very
rare.
(4) Involvement of ﬁbrosis and the wound model in
radiation-induced marrow neoplasms
One could speculate from recent research that
radiation inﬂammation, observed as a low to high
dose-dependent effect in atomic-bomb survivors
(Hayashi et al. 2008), and associated ﬁbrosis, may
be important factors not only for radiogenic bone
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cell content of adult marrow increases with aging and
irradiation, and probably contributes to increased
inﬂammation due to hormonal effects of the ‘fat
hormone’ leptin (Iikuni et al. 2008). Myelodysplastic
syndrome (MDS), sometimes called preleukaemia, is
a clonal disorder of HSC (Kuramoto et al. 2002).
MDS is also associated with both aged and irradiated
marrow. MDS patients present more angiogenesis in
bone marrow than normal (Medinger and Mross
2010). The resulting increase in radiosensitivity
may be a factor in the MDS excess relative risk
being *13 Gy
71 in atomic-bomb survivors, which is
much higher than the risk of leukaemia, 3.8 Gy
71
and all other cancers, 0.3 Gy
71 (Pierce et al. 1996,
Tsukasaki et al. 2007). Higher occurrences of ﬁbrosis
and MDS are also prominent in Thorotrast adminis-
tered to patients (Visfeldt and Andersson 1995,
Ishikawa et al. 2001). The ineffective hematopoiesis
and marked reticulin ﬁbrosis displayed by MDS and
caused by high radiation doses or chemotherapy can
lead to AML/erythroleukaemia or marrow failure. As
shown earlier (Table III), the AML incidence as a
percentage of the total leukaemias is enhanced in
atomic-bomb survivors (2-fold) and Thorotrast
patients (3-fold) compared with the spontaneous
incidence rate. A quarter of the AML cases were
erythroleukaemias in Danish Thorotrast patients,
whereas only a few percent occur spontaneously
(Visfeldt and Andersson 1995).
Transforming growth factor b1 (TGF-b1) is
elevated in plasma during radiotherapy and involved
in the proliferation of MSC, which lead to reticulin
and collagen ﬁbrosis in bone marrow by ﬁbroblasts
(Martin et al. 2000). TGF-b1 is a cytokine that
regulates defence response to injury. Latent TGF-b1
is activated by ROS from radiation and other
sources/stresses such as chemicals or heat (Jobling
et al. 2006). Progenitor cells from patients with
MDS-derived AML display a mixed response to
TGF-b, with AML cells in only four of seven cases
escaping TGF-b mediated growth inhibition (Kosch-
mieder et al. 2001). The involvement of TGF-b1i s
more transparent in transforming pre-leukeamic cells
with the TEL-AML1 chimeric fusion gene into
childhood ALL (Ford et al. 2009). The biological
mechanism transforming MDS to AML/erythroleu-
kaemia is complex and as yet unclear. However,
recent research suggests that radiation’s ability to
produce inﬂammation and ﬁbrosis may be important
factors in the induction of not only bone cancer but
also leukaemia.
Discussion
The former ICRP target, the 10 mm thin endosteum
may be a questionable size for a target as a measure
of radiation dose and risk, because of the genetic
instability observed in bystander non-irradiated
marrow stem cells and progeny (Kadhim et al.
2004): this could be due to a radiation-induced
inﬂammatory response (Lorimore et al. 2005). Cell-
to-cell signalling regulates, in part, cell growth,
differentiation and apoptosis. It is conceivable that
radiation has an inﬂuence on the niche cells that
regulate stem cell fates by affecting signaling
molecules, the extracellular matrix, and cell adhesion
molecules (Arai and Suda 2007). Therefore, irradiat-
ing support cells of stem- or progenitor-cells may
provoke long-range detrimental biological effects due
to disruption of the support cell’s communication.
To be accurate, it is only the haematopoitic tissue
which constitutes a leukaemia target rather than
whole red bone marrow that ICRP (ICRP 23 1975)
describes as consisting of 40% fat cells in addition to
hematopoietic tissue in adults. The age-dependent
alpha-particle dosimetry of hematopoietic marrow,
rather than red marrow, was ﬁrst carried out
employing analytical methods (Richardson et al.
1991), whereas more sophisticated Monte Carlo
simulations enable alpha- and beta-radiation dosi-
metric analyses of the skeleton, both in the quiescent
(Eckerman and Stabin 2000, Richardson and Du-
beau 2003, Watchman et al. 2005) and remodelling
states (Richardson et al. 2007, Nie and Richardson
2009). For a minority of radionuclides and com-
pounds, the dose to hematopoietic marrow and
adipocytes can be markedly different and at variance
with the average dose to homogeneous red marrow.
This dose variation can occur for short-range
radiations and radionuclides of elements or com-
pounds that have higher activities in either adipocytes
e.g. carbon, radon (high gaseous solubility), or
alternatively, higher activities in hematopoietic tis-
sue, such as plutonium (Leggett 1985) as well as the
lean tissue seekers, potassium and polonium. A
representative dose for the whole skeleton by short
range irradiation of bone cancer and leukemic targets
can be obtained by summing dose to these targets in
various bones, weighted by a factor involving the
trabecular or cortical bone’s cellularity, an indicator
of proliferative capacity (Richardson et al. 1991). If
this weighting process is applied to the proposed
ICRP target, the cortical medullary endosteum, in
essence, has virtually no inﬂuence on the radiation
dose to the bone cancer target at any age.
Increasing the peripheral marrow layer from
10 mmt o5 0mm will affect the alpha particle dose
to the bone cancer target from activity located in
trabecular bone or marrow (Nie and Richardson
2009). This is due to the limited maximum range of
alpha particles, e.g., 10 mm in soft tissue for
144Nd,
1.8 MeV particles and 90 mm for
212Po, 8.8 MeV.
The same is true for low energy, shorter-range beta-
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14C with a mean range of 40 mmi n
water. Alpha-particle activity was modeled by Nie
and Richardson (2009) as a uniform source in bone
marrow, bone volume and on bone surface. The
ICRP’s decision to move to a 50 mm marrow layer
results in a relatively small increase in dose to the
bone cancer target from alpha-emitters deposited in
marrow, e.g., Thorotrast. Conversely, a relatively
large decrease in target dose results from alpha-
emitters homogeneously deposited in bone volume,
and particularly for alpha-emitters on bone surface.
The ratio comparing the 50 mm peripheral marrow
dose to the 10 mm endosteum dose is around 1:3.4
for
226Ra,
224Ra and
239Pu on bone surface, and
1:4.3 for
232Th. The ratio of the doses is 1:5 for
alpha- or beta-particles with a range equal to or less
than the width of the endosteum, e.g.,
144Nd.
Therefore, by employing the 50-mm target over the
10 mm one, the ICRP will effectively reduce by as
much as 5-fold the alpha-particle target dose from
bone-volume and bone-surface seekers, which in
turn lessens the predicted risk of bone cancer (and
conversely, increases the RBE more in line with
ICRP recommendations).
Fractional weighting of the endosteum and central
marrow regions could be chosen based on the
calculated leukemic target dose and risk, and
compared with the corresponding excess leukaemia
observed in epidemiological studies. A 10 mm thick
endosteum takes up only about 4% of the trabecular
marrow cavity volume of an adult; however this rises
to *9% for the newborn. These values are derived
assuming the dimensions and morphology of a
‘‘spherical’’ trabecular cavity, as evaluated by
Richardson and Dubeau (2003). The proposed
ICRP target of average dose to trabecular red bone
marrow in effect weighs the dose to the endosteum
and central marrow regions by a ratio of about 1:24
and 1:10 for adults and newborn, respectively.
However, taking account of the radioprotection of
the hypoxic endosteum and a maximum OER of 3
and 2 for low-and high-LET irradiation, the 10-mm
endosteum to central marrow dose ratio would be
weighted by about 1:48 and 1:20 for adults and
newborn exposed to high-LET radiation. This places
less emphasis on the dose to the endosteum and for
bone-seeking alpha-emitters, e.g.,
226Ra, would
lessen the overall dose to the leukemic target and
go some way, besides cell killing, to explaining the
virtual lack of excess leukaemias in radium studies
(Spiers et al. 1983, BEIR IV 1988). It is worth
noting that modiﬁed weighting of dual non-over-
lapping, hematopoietic targets does not greatly
change the leukemic dose and risk assessment for
homogeneous irradiation of whole marrow by
external or internal sources, e.g., atomic-bomb
gamma rays or Thorotrast.
The use of the marrow targets proposed here will
require considerable changes to dosimetric methods
presently employed by ICRP to ascertain radiation
dose and risk. Firstly, new dosimetric methods are
needed to assess the radiation dose to the peripheral
marrow associated with both the quiescent bone
surface and bone remodelling. Nie and Richardson
(2009) conducted a dynamic simulation that studies
the temporal changes of short-range radionuclides
incorporated in a trabecular bone remodelling
compartment. This compartment consists of a
well-oxygenated vascular microenvironment located
within a canopy of bone-lining cells. Angiogenesis,
and consequently the radiosensitivity of marrow, is
enhanced in the vicinity of bone remodelling. The
stem/progenitor cells participating in bone remodel-
ling are in close proximity to radioactivity incorpo-
rated in new bone. Secondly, biokinetic models
provide the temporal variation in radioactivity from
an internal exposure. The models currently em-
ployed by the ICRP do not have compartments
speciﬁcally assigned to marrow targets associated
with bone-remodelling. A physiological skeletal
biokinetic model has been developed that differ-
entiates between quiescent and forming bone
surfaces (Richardson, 2010). This modiﬁcation is
essential for meaningful risk assessment of marrow
neoplasms arising from irradiating infants and
children.
The development of cancer is a multistage process;
animal studies have shown radiation to induce more
initiation than promotion events (BEIR VII 2006). It
is well known that radiation has an enhanced ability,
compared to mitochondrial-generated ROS, to cause
DNA double-strand breaks and presumably, cancer-
initiating chromosome translocations. The evidence
points to obstetric X-rays initiating childhood
leukaemia in utero with no dose threshold (Bithell
and Stewart 1975). But there again, radiation-
induced inﬂammation and ﬁbrosis appears to have
a mainly promotional role in adult bone cancers.
Pre-existing lesions play a similar role. Paget’s
disease of bone is present in around 2% of
individuals of European ancestry and has an age-
threshold of *45 years. The average skeletal dose
threshold of about 10 Gy evident for the induction of
bone tumours in radium dial painters (Evans et al.
1969) may be partly due to premature aging,
advancing Paget’s disease and the shortening of the
cancer latent period in these young women of mainly
European descent. However, even this strong case
for a dose threshold for bone cancer incidence after
ingestion of radium by dial painters is disputed by
Leenhouts and Brugmans (2000) who employ a two-
mutation carcinogenesis model that supports a
linear-quadratic dose-effect relationship with low-
ered risk at low dose.
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Partitioning the ICRP dosimetry targets of trabecular
whole bone marrow (into central marrow and
endosteum) and peripheral marrow (into quiescent
and forming bone surfaces) will improve the risk
assessments for radiation-induced leukaemia and
primary bone cancer, especially for children. A
summary of the main points:
. Rarity in Japanese of Paget’s disease of bone,
characterised by hypervascular marrow and focal
increases in bone turnover, is a factor in the lack
of excess bone cancers in adult atomic-bomb
survivors.
. Pre-existing lesions are not an important pre-
requisite for radiogenic bone cancer in children
whereas growth is, therefore supporting the
additional target of peripheral marrow adjacent
to forming bone surfaces.
. Quiescent, normal stem cells and cancer-initiat-
ing cells reside in a hypoxic niche located in the
endosteum layer and have approximately a 2- to
3-fold greater degree of radioprotection com-
pared to vascular niches.
. HSC and MSC migrate to microvessels to
repopulate the blood cells and remodel bone:
Cancer stem cells similarly occupy or create
vascular niches to produce malignant progeny
and metastasise. Morphological and epidemiolo-
gical evidence, as well as variable niche radio-
sensitivity, supports the need to partition the
ICRP’s whole marrow and peripheral marrow
targets.
. It is suggested that stem cells in central marrow
migrate to the hypoxic endosteum after a radia-
tion exposure as an adaptive response, thereby
showing temporal variation in target location.
. Radiation-induced inﬂammation, ﬁbrosis and
consequent progression in pathogenesis from a
non-malignant to malignant form support a
‘radiation wound to malignancy’ model for bone
cancer and perhaps leukaemia.
. To assess the risk of bone cancer, especially in
children, requires new biokinetic compartmen-
tal models to calculate the radiation dose
associated with forming bone surfaces and
growth plates.
. There are indications that radiation at low doses
can induce chromosome translocations and at
higher doses accelerate aging by inﬂammation,
shorten the cancer latent period, and advance
ﬁbrosis/MDS and stem cell senescence.
The aim of this paper is to propose radiation dose
targets, based on current knowledge, for assessing
the risk of inducing marrow neoplasms, especially for
the third trimester fetus, infants and children.
However, there are many uncertainties, such as the
exact origin of cancer stem cells and radiation’s
contribution to the carcinogenic process, especially
at low doses. Therefore, the proposed hematological
targets have a speculative element until there is better
clariﬁcation of radiation’s role in the cancer stem cell
process which may well differ for childhood and
adult cancers. Consequently, like the ICRP targets,
the targets proposed here will need future modiﬁca-
tion as biological and epidemiological knowledge
advances.
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